NASDAQ: IMRX - Immuneering Corporation

Yield per half year: -44.25%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Immuneering Corporation

Extended chart Simple chart
Financial Markets by TradingView

About Immuneering Corporation

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 currently in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2021-07-30
ISIN US45254E1073
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://immuneering.com
Цена ао 1.54
Change price per day: +3.9% (1.54)
Change price per week: +5.26% (1.52)
Change price per month: -12.09% (1.82)
Change price per 3 month: -2.14% (1.635)
Change price per half year: -44.25% (2.87)
Change price per year: -44.83% (2.9)
Change price per 3 year: -76.95% (6.94)
Change price per 5 year: 0% (1.6)
Change price per 10 year: 0% (1.6)
Change price per year to date: -28.89% (2.25)
All parameters

Underestimation

Title Value Grade
P/S 467155.72 1
P/BV 2.35 6
P/E 0 0
EV/EBITDA -2.73 0
Total: 3.5

Efficiency

Title Value Grade
ROA, % -52.12 0
ROE, % -59.03 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0774 10
Total: 8.6

Growth impulse

Title Value Grade
Yield Revenue, % -99.98 0
Yield Ebitda, % 695.35 10
Yield EPS, % 100.27 10
Total: 8
More

Institutions Volume Share, %
Cormorant Asset Management, LP 4204364 14.36
Price (T.Rowe) Associates Inc 3378100 11.54
Blackrock Inc. 2097406 7.16
Citadel Advisors Llc 2078092 7.1
Vanguard Group Inc 1073815 3.67
FMR, LLC 489447 1.67
Goldman Sachs Group Inc 457059 1.56
Geode Capital Management, LLC 444233 1.52
State Street Corporation 373662 1.28
HighVista Strategies LLC 254513 0.87

ETF Share, % Profitability for 1 year, % Dividends, %
Range Cancer Therapeutics ETF 1.07445 47.24 0.11955
iShares Micro-Cap ETF 0.01885 17.09 1.54048



Head Job title Payment Year of birth
Dr. Benjamin J. Zeskind M.B.A., Ph.D. Co-Founder, President, CEO & Director 935.09k 1983 (42 years)
Dr. Brett M. Hall Ph.D. Chief Scientific Officer 905.41k 1969 (56 years)
Ms. Mallory Morales CPA Principal Financial & Accounting Officer, Chief Accounting Officer and Treasurer N/A 1984 (41 year)
Ms. Paula George CPA Director of Accounting & Operations and Assistant Corporate Controller N/A
Mr. Michael D. Bookman J.D. Chief Legal Officer & Secretary N/A 1987 (38 years)
Ms. Leah R. Neufeld Chief People Officer N/A 1973 (52 years)
Dr. Peter King Ph.D. Head of Discovery & VP N/A
Dr. Praveen Nair Ph.D. Head of Translational Pharmacology & VP N/A
Mr. Harold E. Brakewood Chief Business Officer 579.77k 1966 (59 years)
Mr. Robert J. Carpenter M.B.A., M.S. Co-Founder & Chair Emeritus 75.36k 1946 (79 years)

Address: United States, Cambridge. MA, 245 Main Street - open in Google maps, open in Yandex maps
Website: https://immuneering.com